-
EP3233843
European procedure
Extract from the Register of European Patents
EP About this file: EP3233843
| EP3233843 - ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 21.08.2020 Database last updated on 30.07.2024 | |
| Former | The patent has been granted Status updated on 13.09.2019 | ||
| Former | Grant of patent is intended Status updated on 09.05.2019 | ||
| Former | Examination is in progress Status updated on 19.04.2019 | ||
| Former | Grant of patent is intended Status updated on 06.03.2019 | ||
| Former | Examination is in progress Status updated on 01.06.2018 | ||
| Former | Request for examination was made Status updated on 22.09.2017 | ||
| Former | The international publication has been made Status updated on 30.06.2017 | Most recent event Tooltip | 21.08.2020 | No opposition filed within time limit | published on 23.09.2020 [2020/39] | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2019/42] |
| Former [2017/43] | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | Inventor(s) | 01 /
FU, Jiping Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, California 94608 / US | 02 /
JIN, Xianming Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, California 94608 / US | 03 /
KARUR, Subramanian Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, California 94608 / US | 04 /
LAPOINTE, Guillaume Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, California 94608 / US | 05 /
MADERA, Ann Marie Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, California 94608 / US | 06 /
SWEENEY, Zachary Kevin Novartis Institutes for BioMedical Research Inc. 5300 Chiron Way Emeryville, California 94608 / US | [2017/43] | Representative(s) | Weickmann & Weickmann PartmbB Richard-Strauss-Strasse 80 81679 München / DE | [2019/42] |
| Former [2017/43] | Marti, Christiane Novartis Pharma AG Patent Department 4002 Basel / CH | Application number, filing date | 15816893.0 | 15.12.2015 | [2017/43] | WO2015IB59631 | Priority number, date | US201462092402P | 16.12.2014 Original published format: US 201462092402 P | [2017/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016097995 | Date: | 23.06.2016 | Language: | EN | [2016/25] | Type: | A1 Application with search report | No.: | EP3233843 | Date: | 25.10.2017 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.06.2016 takes the place of the publication of the European patent application. | [2017/43] | Type: | B1 Patent specification | No.: | EP3233843 | Date: | 16.10.2019 | Language: | EN | [2019/42] | Search report(s) | International search report - published on: | EP | 23.06.2016 | Classification | IPC: | C07D413/06, A61K31/42, C07D413/12, C07D261/08 | [2017/43] | CPC: |
C07D261/08 (EP,CN,EA,IL,KR,US);
A61K31/42 (EP,EA,IL,KR,US);
A61K45/06 (EP,EA,IL,KR,US);
A61K31/422 (EP,EA,IL,KR,US);
A61P11/00 (EP);
A61P31/04 (EP,IL);
A61P9/00 (EP);
C07D413/06 (EP,EA,IL,KR,US);
C07D413/12 (EP,CN,EA,IL,KR,US);
| C-Set: |
A61K31/422, A61K2300/00 (US,EP);
A61K31/42, A61K2300/00 (EP,US) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/43] | Extension states | BA | 17.07.2017 | ME | 17.07.2017 | Validation states | MA | 17.07.2017 | Title | German: | ISOXAZOL-HYDROXAMSÄUREVERBINDUNGEN ALS LPXC-INHIBITOREN | [2019/13] | English: | ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS | [2017/43] | French: | COMPOSÉS D'ACIDE ISOXAZOLE HYDROXAMIQUE COMME INHIBITEURS DE LPXC | [2019/13] |
| Former [2017/43] | ISOXAZOLHYDROXAMSÄUREVERBINDUNGEN ALS LPXC-INHIBITOREN | ||
| Former [2017/43] | COMPOSÉS D'ACIDES D'ISOXAZOLE EN TANT QU'INHIBITEURS DE LPXC | Entry into regional phase | 17.07.2017 | National basic fee paid | 17.07.2017 | Designation fee(s) paid | 17.07.2017 | Examination fee paid | Examination procedure | 29.06.2017 | Amendment by applicant (claims and/or description) | 29.06.2017 | Date on which the examining division has become responsible | 17.07.2017 | Examination requested [2017/43] | 05.06.2018 | Despatch of a communication from the examining division (Time limit: M06) | 21.11.2018 | Reply to a communication from the examining division | 07.03.2019 | Communication of intention to grant the patent | 17.04.2019 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 10.05.2019 | Communication of intention to grant the patent | 04.09.2019 | Fee for grant paid | 04.09.2019 | Fee for publishing/printing paid | 04.09.2019 | Receipt of the translation of the claim(s) | Opposition(s) | 17.07.2020 | No opposition filed within time limit [2020/39] | Fees paid | Renewal fee | 12.12.2017 | Renewal fee patent year 03 | 30.11.2018 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [AD]WO2010032147 (PFIZER [US], et al) [AD] 1-25* examples 1,10,16; claims 1-15 *; | [AD]WO2011073845 (PFIZER [US], et al) [AD] 1-25 * examples 65,67; claims 1-16 *; | [AD]WO2012137094 (PFIZER [US], et al) [AD] 1-25 * examples 2,5,6,8; claims 1-14; tables 4-5 * | by applicant | EP0090505 | WO9920758 | WO9940196 | US6111090 | WO0103720 | WO2004062601 | WO2004078163 | WO2005007190 | WO2005055808 | WO2005115451 | US7025962 | WO2006083289 | WO2006121168 | WO2007005874 | WO2007133822 | EP1866339 | WO2009101611 | WO2009114335 | US7618632 | WO2010003118 | US2010028330 | WO2010019570 | EP2161336 | WO2010027827 | WO2010032147 | WO2010077634 | US7812135 | WO2011028683 | WO2011051726 | US7943743 | WO2011066342 | WO2011073845 | US2011150892 | WO2011090754 | US8008449 | US2012039906 | US2012114649 | WO2012120397 | WO2012137094 | US8354509 | US8388967 | WO2013039954 | WO2013079174 | EP1947183 | US8586023 | US8591886 | US8609089 | WO2014008218 | - MDLULI ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (2006), vol. 50, no. 6, pages 2178 - 2184 | - OKAZAKI ET AL., CURR OPIN IMMUNOL, (2002), vol. 14, pages 391779 - 391782 | - BENNETT ET AL., J. IMMUNOL., (2003), vol. 170, pages 711 - 718 | - ISHIDA, Y. ET AL., EMBO J., (1992), vol. 11, pages 3887 - 3895 | - BLANK, C. ET AL., IMMUNOL. IMMUNOTHER, (20061229), vol. 56, no. 5, pages 739 - 745 | - DONG ET AL., J. MOL. MED, (2003), vol. 81, pages 281 - 287 | - BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER, (2005), vol. 54, pages 307 - 314 | - KONISHI ET AL., CLIN. CANCER RES., (2004), vol. 10, pages 5094 - 5100 | - IWAI ET AL., PROC. NAT'L. ACAD. SCI. USA, (2002), vol. 99, pages 12293 - 12297 | - BROWN ET AL., J. IMMUNOL., (2003), vol. 170, pages 1257 - 1266 | - HAMID, O. ET AL., NEW ENGLAND JOURNAL OF MEDICINE, (2013), vol. 369, no. 2, pages 134 - 144 | - Science of Synthesis: Houben-Weyl Methods of Molecular Transformation, GEORG THIEME VERLAG, (2005), vol. 48, page 41627 | - The Peptides, ACADEMIC PRESS, (1981), vol. 3 | - HOUBEN WEYL, Methoden der organischen Chemie, GEORG THIEME VERLAG, (1974), vol. 15/1 | - TETRAHEDRON LETT., (1980), vol. 21, page 3111 | - TETRAHEDRON, (2004), vol. 60, page 11421 | - HYLAND ET AL., JOURNAL OF BACTERIOLOGY, (1997), vol. 179, pages 2029 - 2037 |